Literature DB >> 14636956

Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses.

Rafael Maldonado1, Olga Valverde.   

Abstract

Several anatomical, biochemical and pharmacological evidence support the existence of bidirectional interactions between cannabinoid and opioid systems. The present review is focused on the participation of the endogenous opioid system in the antinociceptive and emotional-like responses induced by cannabinoids, and the development of tolerance to cannabinoid pharmacological effects. Cannabinoid and opioid agonists produce antinociception by acting on similar structures within the central nervous system, and a peripheral mechanism has been also proposed for both compounds. Pharmacological studies have suggested that the endogenous opioid system could be involved in cannabinoid antinociception and the development of cannabinoid tolerance. Recent studies using knockout mice have also demonstrated the role of the opioid system in cannabinoid antinociception and tolerance, although some discrepancies with the previous pharmacological results have been reported when using knockout mice. On the other hand, cannabinoid administration can induce anxiolytic-like responses that are mediated at least in part by an endogenous opioid activity on micro- and delta-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636956     DOI: 10.1016/j.euroneuro.2003.08.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  18 in total

Review 1.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

2.  Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.

Authors:  Marcello Solinas; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2004-12-24       Impact factor: 4.530

Review 3.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 4.  Pain and the context.

Authors:  Elisa Carlino; Elisa Frisaldi; Fabrizio Benedetti
Journal:  Nat Rev Rheumatol       Date:  2014-02-25       Impact factor: 20.543

Review 5.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

Review 6.  Interaction of Cannabis Use and Aging: From Molecule to Mind.

Authors:  Hye Bin Yoo; Jennifer DiMuzio; Francesca M Filbey
Journal:  J Dual Diagn       Date:  2019-09-30

Review 7.  Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics.

Authors:  Michael Remesic; Victor J Hruby; Frank Porreca; Yeon Sun Lee
Journal:  ACS Chem Neurosci       Date:  2017-04-07       Impact factor: 4.418

8.  Identification of two novel, potent, low-liability antinociceptive compounds from the direct in vivo screening of a large mixture-based combinatorial library.

Authors:  Kate J Reilley; Marc Giulianotti; Colette T Dooley; Adel Nefzi; Jay P McLaughlin; Richard A Houghten
Journal:  AAPS J       Date:  2010-04-27       Impact factor: 4.009

9.  Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors.

Authors:  Jillian L Scavone; Ken Mackie; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2009-11-18       Impact factor: 3.252

10.  Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.

Authors:  Javier Garzón; Elena de la Torre-Madrid; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Pilar Sánchez-Blázquez
Journal:  Mol Pain       Date:  2009-03-10       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.